The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Texas MPN Workshop 2020 | MPNs as a disease spectrum: are genomics the key to one’s destiny?
Raajit Rampal
• 27 Aug 2020
Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, gives his thoughts on classifying myeloproliferative neoplasms (MPNs) into further sub-divisions, the role of genomics and where we go from here. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
